Impressive Result of Gemcitabine and Cisplatin Combination Therapy in Post-Operative Residual  Cholangiocarcinoma Patient Presenting with Hyperbilirubinemia, an Experience in Indonesian  Tertiary Hospital

Ibnu Purwanto; Agus Barmawi; Bambang Purwanto Utomo; Ahmad Ghozali

doi:10.22146/actainterna.62846

Impressive Result of Gemcitabine and Cisplatin Combination Therapy in Post-Operative Residual Cholangiocarcinoma Patient Presenting with Hyperbilirubinemia, an Experience in Indonesian Tertiary Hospital

https://doi.org/10.22146/actainterna.62846

Ibnu Purwanto^(1*), Agus Barmawi⁽²⁾, Bambang Purwanto Utomo⁽³⁾, Ahmad Ghozali⁽⁴⁾

(1) Hematology and Medical Oncology Division, Internal Medicine Department, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital
(2) Digestive Surgery Department, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital
(3) Radiology Department, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital
(4) Anatomical Pathology Department, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital
(*) Corresponding Author

Abstract

Introduction: Cholangiocarcinoma (CCA) often presents at an inoperable or an advanced stage in which complete resection is not possible. In such scenario, chemotherapy often is the only option to improve patient’s survival. Severe hyperbilirubinemia, often associated with higher risk of developing chemotherapy-related adverse event, might complicates one’s decision in choosing chemotherapy regimen. Case Report: We present a case of 63-year-old post-operative CCA patient with residual mass and severe hyperbilirubinemia. The patient completed six cycles of gemcitabine (1000 mg/m², day 1 and 8) and cisplatin (70 mg/m², day 1) every 3 weeks with tolerable side effect. No sign of residual tumor was observed on CT-Scan performed one-month post chemotherapy. Conclusion: Combination of cisplatin and gemcitabine may offer safe treatment option for post-operative residual CCA patient presenting with hyperbilirubinemia.

Keywords

Cholangiocarcinoma; Gemcitabine; Cisplatin; Chemotherapy; Hyperbilirubinemia: Indonesia

Full Text:

PDF

References

1. Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol 2015; 29: 221-232.

2. Ladep NG, Khan SA, Crossey MM, et al. Incidence and mortality of primary liver cancer in England and Wales: changing patterns and ethnic variations. World J Gastroenterol 2014; 20:1544-1553.

3. Shin HR, Oh JK, Masuyer E, et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci 2010; 101: 579-585.

4. van Kaick G, Wesch H, Lührs H, et al. Neoplastic diseases induced by chronic alpha-irradiation--epidemiological, biophysical and clinical results of the German Thorotrast Study. J Radiat Res 1991; 32: 20-33.

5. Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management ofintrahepatic cholangiocarcinoma. J Hepatol 2014; 60: 1268-1289. 6. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011;

8: 512-522. 7. haveri KS, Hosseini-Nik H. MRI of cholangiocarcinoma. J Magn Reson Imaging 2015; 42: 1165-1179. 8. Ringe KI, Wacker F. Radiological diagnosis in cholangiocarcinoma: Application of computed tomography, magnetic resonance imaging, and positron emission tomography. Best Pract Res Clin Gastroenterol 2015; 29: 253-265.

9. Valle J W, Borbath I, Khan SA, et al. ESMO Guidelines Committee. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: 28-37.

10. Eckmann KR, Patel DK, Landgraf A, et al. Chemotherapy Outcomes for the Treatment of Unresectable Intrahepatic and Hilar Cholangiocarcinoma: A Retrospective Analysis. Gastrointest Cancer Res 2011; 4: 155–160.

11. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281.

12. Razumilava N, Gores GJ. Combination of gemcitabine and cisplatin for biliary tract cancer: a platform to build on. J Hepatol 2011; 54: 577-578.

13. Field KM, Michael M. Part II: Liver function in oncology: towards safer chemotherapy use. Lancet Oncol 2008; 9: 1181-1190.

14. Field KM, Dow C, Michael M. Part I: Liver function in oncology: biochemistry and beyond. Lancet Oncol 2008; 9: 1092-101.

15. Antwi SO, Mousa OY, Patel T. Racial, Ethnic, and Age Disparities in Incidence and Survival of Intrahepatic Cholangiocarcinoma in the United States; 1995-2014. Ann Hepatol 2018; 17: 274-285.

DOI: https://doi.org/10.22146/actainterna.62846